TY - JOUR
AR - ACO-2020-2-103
TI - Hand and Foot Syndrome Associated with Capecitabine
AU - Louai , Alsaloumi
AU - Shaima , Shawagfeh
AU - Bilgen , Başgut
JO - Annals of Clinical Oncology
PY - 2020
DA - Tue 25, Aug 2020
SN - 2674-3248
DO - http://dx.doi.org/10.31487/j.ACO.2020.02.03
UR - https://www.sciencerepository.org/hand-and-foot-syndrome-associated-with-capecitabine_ACO-2020-2-103 
KW - Capecitabine, hand and foot syndrome, palmar-plantar erythrodysesthesia, celecoxib, pyridoxine
AB - Having cancer impacts the patient both psychologically and physically. However, if cancer is accompanied
with HFS, the patient’s condition gets even worse. Capecitabine is a prodrug approved to treat several types
of cancer such as breast and colorectal cancer. It is associated with several adverse effects such as hand and
foot syndrome (HFS) which mostly affects the palms and legs. The provoked mechanisms of HFS are not
clear yet. They require further validation of HFS pathogenesis. Up to now, prevention and treatment of HFS
are not clearly solidified. Evidence supports the use of celecoxib, urea-based creams, and vitamin E to
reduce the severity and the incidence of HFS. This review aims to provide the gaps and ways to further
clinical evaluations.